What Older Adults Need To Know About Measles And Shingles Vaccines [Forbes]
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: Forbes
What Older Adults Need To Know About Measles And Shingles Vaccines By Stephenie Overman, Next Avenue Getty You probably know there’s a measles outbreak. And you may have heard that there’s a shortage of the most effective vaccine to prevent shingles, a cousin of the childhood disease chickenpox. Did you know that both viruses are especially bad news for older Americans? “What’s true for both diseases is that they are more severe the older you get,” says Dr. Gregory Poland, director of the Mayo Clinic Vaccine Research Group in Rochester, Minn. “We think back to childhood and most kids did fine. But above age 50, people start having complications. We have no treatment. The only recourse is prevention,” Poland says. Also on Forbes: Measles Cases Increasing As of May 13, the number of measles cases Measles is an infectious viral disease usually associated with fever and a red rash. But it can be much worse. Some people suffer severe complications, such as pneumonia or encephalitis (swelli
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GSK plc American Depositary Shares (Each representing two Ordinary Shares) news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK plc (NYSE: GSK) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating.MarketBeat
- GSK plc (NYSE: GSK) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $39.50 price target on the stock, down previously from $53.00.MarketBeat
- GSK plc (NYSE: GSK) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.MarketBeat
- GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy' [Seeking Alpha]Seeking Alpha
- New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV DiseaseBusiness Wire
GSK
Sec Filings
- 11/19/24 - Form 6-K
- 11/19/24 - Form 6-K
- 11/14/24 - Form 6-K
- GSK's page on the SEC website